Q3 2020 Sales Performance

HIV: Leading core agent in HIV treatment Dolutegravir is #1 core agent globally 500,000 patients worldwide taking a dolutegravir based regimen Unmatched trial results; superiority in 5 studies and data in broad populations VS. efavirenz VS. raltegravir VS. darunavir VS. atazanavir VS. lopinavir Superior (naive) Superior (experienced) Superior (naive) Superior (women/naive) Superior (experienced) Varia DAWNING We Th SINGLE SAILING FLAMINGO gsk SINGLE, FLAMINGO, SAILING, ARIA and DAWNING were non-inferiority studies with a pre- specified analysis for superiority. Table shows primary endpoint outcomes. *Patient Pathways survey presented at IAS 2017 DHHS: Department of Health and Human Services; EACS: European AIDS Clinical Society 28

View entire presentation